Vascular endothelial growth factor (VEGF) upregulation is a known biomarker of poor prognosis in mucosal melanoma [109] and clinical data support the combination of antiangiogenic and immunotherapeutic agents in this population. Here, VEGFA is linked to mucosal melanoma.